Trials / Completed
CompletedNCT02684266
A Study of SHR6390 in Advanced Solid Tumor Patients
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Solid Tumor Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced solid tumor patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6390 | SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD |
Timeline
- Start date
- 2016-03-03
- Primary completion
- 2019-06-28
- Completion
- 2019-06-28
- First posted
- 2016-02-17
- Last updated
- 2022-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02684266. Inclusion in this directory is not an endorsement.